Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prospective safety and effectiveness study of tocilizumab in rheumatoid arthritis
ChiCTR2000032678Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Peking Union Medical College Hospital. Primary endpoint: Disease Activity Score in 28 joints. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2000032678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032678.